The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | XPO1 inhibition with selinexor for RRMM
Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, discusses XPO1 inhibition with selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM). This drug is approved in this setting in combination with bortezomib and dexamethasone based on the STORM (NCT02336815) and the BOSTON (NCT03110562) trials. It is a potential option for patients who are triple-class refractory or for bridging to CAR-T therapy. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
